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Abstract
Background: The prevalence of otitis media in Greenlandic children is one of the highest in the world.
International studies have shown that otitis-prone children may benefit from tubulation of the tympanic
membrane. However, it is unknown whether these results can be applied to Greenlandic children and trials on
the effects of ventilation tubes in high-risk populations have, to our knowledge, never been conducted.
Methods: The trial is an investigator-initiated, multicentre, randomized, blinded superiority trial of bilateral
ventilation tube insertion versus treatment as usual (no tube) in Greenlandic children aged 9–36 months with
chronic otitis media with effusion or recurrent acute otitis media. With randomization stratified by otitis media
subtype and trial site, a type 1 error of 5% and a power of 80%, a total of 230 participants are needed to detect a
decrease of two visits to a health clinic during 2 years, which is considered the minimal clinical relevant difference.
The primary outcome measure will be assessed blindly by investigating medical records. Secondary outcome
measures are number of episodes of acute otitis media, quality of life, number of episodes of antibiotics
administration and proportion of children with tympanic membrane perforations.
Discussion: This trial will provide evidence-based knowledge of the effects of ventilation tubes in children with
middle ear infections from the high-risk Greenlandic population. Furthermore, this trial will improve the
understanding of conducting randomized clinical trials in remote areas, where management of logistical aspects is
particularly challenging.
Trial registration: ClinicalTrials.gov, NCT02490332. Registered on 14 February 2016.
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Background
Otitis media is one of the most common reasons for
children to contact health clinics and insertion of venti-
lation tubes in the tympanic membrane remains the
most frequent type of paediatric surgery in the USA as
well as the main reason for prescription of out-of-
hospital antibiotics to paediatric patients [1–3]. The
worldwide socioeconomic consequences of the disease
are substantial, owing to treatment and management of
the disease and parental absence from work [4].
The prevalence of otitis media and other acute respira-
tory tract infections in Greenlandic children is one of
the highest in the world; 20% of schoolchildren have im-
paired hearing in the frequencies of normal speech [5–10].
This pattern is also seen in, for example, the indigenous
population in Australia [11]. Many theories have been sug-
gested to explain the high prevalence in certain indigenous
populations, such as anatomical features, poverty or limited
access to health-care, as well as a high bacterial load in the
nasopharynx [12–15]. Studies have shown that the preva-
lence of chronic suppurative otitis media in the two largest
towns in Greenland, Nuuk and Sisimiut, is 9% to 14%, which
is a public health problem requiring urgent attention, ac-
cording to the World Health Organization [6, 7, 12]. A total
of 91% of children with chronic suppurative otitis media de-
velop permanent hearing loss, which underlines the import-
ance of treatment and management of the disease [9].
Previous studies have shown that risk factors for the
development of chronic suppurative otitis media are as-
sociated with the number of upper respiratory tract in-
fections, as well as attendance of day care, mothers’
educational status, passive smoking and socioeconomic
factors, similar to known risk factors for acute otitis
media found in other studies worldwide [7, 8, 10, 16]. It
has been suggested that children with chronic otitis
media with effusion, as well as recurrent acute otitis
media, are more prone to develop chronic suppurative
otitis media, and treatment of these conditions might
therefore decrease the number of children with chronic
suppurative otitis media [6, 17]. The cumulative inci-
dence of chronic suppurative otitis media in Greenland
is 14% at the age of 4, with the highest hazard rate
between 6 and 12 months [7]. This indicates that the
disease develops early in childhood, and calls for inter-
vention as early as possible in otitis-prone children, to
limit progression to chronic perforations.
Ventilation tubes are inserted in the tympanic mem-
brane to equalize pressure and allow drainage of middle
ear fluid.
According to guidelines from the UK, the USA and
Denmark [1, 3, 18–21], there are two indications for the
insertion of ventilation tubes in children:
 Chronic otitis media with effusion and hearing loss
 Recurrent acute otitis media
Chronic otitis media with effusion is defined as fluid
in the middle ear cavity lasting ≥3 months. Recurrent
acute otitis media is defined as ≥3 episodes of acute oti-
tis media within 6 months or ≥4 episodes of acute otitis
media within 12 months [21].
Guidelines on the treatment of otitis media with effu-
sion are fairly similar and have been recently updated in
both the USA and the UK [3, 20]. However, guidelines
on treatment of recurrent acute otitis media vary and
different guidelines currently exist in the USA, while
there are no national guidelines in the UK [1, 19, 21].
This might explain part of the observed international
differences in the number of ventilation tube insertions
for recurrent acute otitis media [22].
The mentioned international guidelines on treatment
with ventilation tubes are generally based on evidence of
low methodological quality concerning such outcomes as
number of otitis media episodes after treatment, quality of
life after treatment, reduction in chronic tympanic mem-
brane perforations after treatment and number of episodes
of aural discharge after treatment, according to the
GRADE evaluation of quality of evidence [18, 21, 23, 24].
Furthermore, it is primarily children from Western trial
populations, and not children from high-risk otitis-prone
populations, such as the Inuit in Greenland, who have
been randomized in the previous trials. Currently, there
are no national guidelines or programmes to ensure pre-
vention and treatment of otitis media and impaired hear-
ing in Greenland. The Greenlandic Ministry of Health has
considered introducing ventilation tube insertion as a
more consistent treatment modality in order to decrease
the burden of otitis media in the country. However, trials
on the effects of ventilation tubes among children in high-
risk populations have, to our knowledge, never been con-
ducted. We therefore argue that it is both medically and
ethically necessary to conduct a randomized clinical trial
before ventilation tubes are made part of the routine treat-
ment of children with chronic otitis media with effusion
and recurrent acute otitis media in Greenland. Moreover,
ventilation tube treatment is currently not a part of stand-
ard care in Greenland and this provides a unique oppor-
tunity to investigate the unbiased effect of the treatment,
which would not be possible in populations where ventila-
tion tube treatment is already standard treatment.
Methods/Design
Objective and hypothesis
The primary objective of the trial will be to assess the ef-
fects of bilateral insertion of ventilation tubes versus
‘treatment as usual’ with no ventilation tubes in children
9–36 months old with chronic otitis media with effusion
or recurrent acute otitis media in Greenland, measured by
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number of visits to health clinic for 2 years after
randomization, assessed by investigating medical records.
The null hypothesis is:
 There is no difference in the number of visits to
health clinics for children with chronic otitis media
with effusion or recurrent otitis media treated with
bilateral ventilation tubes, compared with children
not treated with ventilation tubes.
Design
We have designed an investigator-initiated, parallel-
group, multicentre, randomized clinical superiority trial
of bilateral ventilation tube insertion versus treatment as
usual (no ventilation tube) in Greenlandic children with
chronic otitis media with effusion or with recurrent
acute otitis media.
The Consolidated Standards of Reporting Trials
(CONSORT) flow chart for the trial is shown in Fig. 1
[25]. The Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) participant timeline is
given in Table 1 and the SPIRIT checklist is given in
Additional file 1 [26].
We will consider all patients followed at a participat-
ing trial site for participation and include patients if they
comply with the inclusion and exclusion criteria listed in
Table 2.
The inclusion procedure is shown in Fig. 2.
We will include children aged 9–36 months. Infants
younger than this age group require special anaesthesio-
logical care, which cannot be offered in Greenland for
ventilation tube insertion. The upper age limit has been
set as low as possible in order to intervene before pro-
gression of the disease, while ensuring adequate sample
size in this small population. We have attempted to re-
duce the number of exclusion criteria to as few as pos-
sible. However, children with orofacial cleft, Down’s
syndrome and immune deficiency are, for other reasons,
known to be at very high risk of chronic otitis media
with effusion and recurrent acute otitis media and are
therefore not comparable with other children. Children
already treated with ventilation tubes can also not be
included.
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) trial flow chart
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Trial site and personnel
The trial sites are hospitals and health clinics in six Green-
landic towns: Nuuk, Sisimiut, Ilulissat, Aasiaat, Qaqortoq
and Tasiilaq. The Greenlandic health-care system is divided
into primary and secondary sectors. The only large and
secondary referral hospital is in the capital, Nuuk [27].
The personnel performing the initial selection and
screening of participants will be the regular staff at the
Greenlandic health clinics and hospitals, for instance
nurses, assistants and doctors of different specialities
and ranks.
Randomization
The enrolment of patients will be conducted by an ear,
nose and throat (ENT) specialist and the coordinating
investigator. We will use centralized stratified web-based
randomization. Prior to randomization, a computer will
generate randomization sequences with varying block
sizes that are unknown to the investigators. An internet-
based randomization system will be set up conducting
randomization stratified according to centre (trial site)
and type of otitis media, i.e., recurrent acute otitis media
or chronic otitis media with effusion at baseline (yes or
no). The randomizing investigator will access the inter-
net site through a personal information number. Patients
who meet both criteria for chronic otitis media with ef-
fusion and recurrent acute otitis media will be consid-
ered in the recurrent acute otitis media group. The
patients will be randomly allocated 1:1 into the two
intervention groups.
Interventions
The experimental intervention consists of bilateral
insertion of ventilation tubes (Donaldson) in the
tympanic membranes, administered under general
anaesthesia.
Short-term ventilation tubes will be used, consistent
with the tube type applied in the majority of other stud-
ies, and in accordance with the type that is expected to
be introduced in Greenland [18, 23]. If the tympanic
Table 1 Participant timeline, Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram
Study period
Time point Enrolment Allocation Close-out
Enrolment: −t1 0 t1 t1 + 3 months t1 + 1 year t1 + 2 years
Eligibility screen X
Informed consent X
Allocation X
Interventions: X
Ventilation tube insertion X X
No ventilation tube insertion X X
Assessments:
Sex, age, ethnicity, socioeconomic factors X
Number of visits to health clinic X
Questionnaires: Otitis Media-6 and Caregiver impact X X X X X
Safety variables X
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Children aged 9–36 months Children with orofacial cleft
Children with at least one Greenlandic born parent and at least one Greenlandic born grandparent Children with Down’s syndrome
American Society of Anaesthesiologists’ physical status classification class 1 and 2 Children with known generalized immune
deficiency
B-type curve, defined as flat line tympanograms or gradient <0.04 ml, or C2-type curve, defined
as pressure≤ −200 dPa, measured by tympanometry at two visits three-four months apart
or
Children formerly treated with ventilation tubes
three episodes of acute otitis media in 6 months according to medical charts
or
Lack of signed informed consent, signed by the
legal guardian
tour episodes of acute otitis media in 12 months according to medical charts
Signed informed consent, signed by the legal guardian
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membrane is infected at the time of ventilation tube in-
sertion, topical antibiotics will be given (Cilodex® [dexa-
methasone + ciprofloxacin] eardrop suspension, 3 mg +
1 mg, dexamethasone + ciprofloxacin) at a dose of four
drops twice daily for 5 days.
If children in the intervention group seek medical assist-
ance for ear problems after the insertion of ventilation
tubes, these ear problems will be treated according to
current practice in Greenland, which includes systemic
antibiotic treatment (amoxicillin 40–90 mg/(kg day)), as
Fig. 2 Inclusion procedure flowchart. AOM, acute otitis media; ENT, ear, nose and throat; OME, otitis media with effusion
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well as aural toilette and topical antibiotics (ciprofloxacin
1 ml/3 mg, three drops, twice daily, or Cilodex® [dexa-
methasone + ciprofloxacin] eardrop suspension, 3 mg +
1 mg, four drops twice daily for 5–7 days).
The control intervention will be based on the current
practice in Greenland, which includes systemic antibiotic
treatment (amoxicillin, 40–90 mg(kg day)), as well as
aural toilette and topical antibiotics (ciprofloxacin 1 ml/
3 mg, three drops, twice daily). Children in the control
group will not be offered ventilation tubes for any cir-
cumstance until at least 2 years after the first ENT visit
and randomization.
Children in both the intervention group and control
group will have an ENT examination, including otoscopy
by an ENT specialist at least once a year and at the end
of the study period, 2 years after randomization.
Outcomes
To assess the primary outcome in as unbiased a manner
as possible, it is necessary to choose an outcome that
does not require visualization of the tympanic mem-
brane, as this might reveal the trial intervention alloca-
tion of the patient (the ventilation tube or sequelae to
such a tube would be visible). Therefore, the primary
outcome will be the number of visits to health clinics
during 2 years after randomization, determined accord-
ing to the medical records, assessed blinded to interven-
tion. In otherwise healthy children, the number of visits
to health clinics can be assumed to reflect the number
of episodes related to the ear or upper respiratory tract,
as this is thought to be the primary reason for contact to
health clinics for children aged 9–36 months [28].
It is currently not possible to assess hearing level as an
outcome measure because there are no facilities available
in Greenland able to meet the high standard of hearing
evaluation, which would be necessary to detect differ-
ences in hearing levels of 4 dB [23]. We therefore postu-
late that an effect of ventilation tubes on otitis media
with effusion might be reflected in a change in the num-
ber of visits to health clinics. The number of episodes of
acute otitis media, based on medical records, will be in-
cluded as a secondary outcome measure but will not be
used as a primary outcome measure because the treat-
ment providers and the outcome assessors will often not
be sufficiently blinded to the trial intervention
allocation.
Primary outcome measure
This is the number of visits to health clinic during
2 years after the randomization, based on medical
records, evaluated by designated assessors blinded to the
intervention.
Secondary outcome measures
1. Number of episodes of acute otitis media during the
2 years after the randomization, based on medical
records, evaluated by designated assessors blinded to
the intervention
2. Quality of life, measured on a 0–100 scale by the
validated Otitis Media-6 questionnaire [29, 30] and
the Caregiver Impact Questionnaire [31, 32],
assessed at randomization, 3 months after
randomization, 1 year after randomization and at
the end of the trial, 2 years after randomization
3. Number of episodes during the 2 years after
randomization where oral or intravenous antibiotics
have been administered, based on medical records,
evaluated by designated assessors blinded to the
intervention
4. Proportion of children with unilateral or bilateral
tympanic membrane perforations in the intervention
and control group at the end of the trial 2 years
after randomization, based on otoscopical photos,
which will be anonymized and evaluated by an ENT
specialist without knowledge of the intervention
5. Serious adverse events during the 2 years after the
randomization: any adverse event that results in
death, is life threatening, requires hospitalization or
prolongation of existing hospitalization or results in
persistent or significant disability or incapacity [33]
Exploratory outcomes
1. Number of episodes of aural discharge during the
2 years after randomization, based on medical
records, evaluated by designated assessors blinded to
the intervention
The primary outcome measure as well as secondary
outcome measures 1 and 3 and the exploratory outcome
measure will be based on medical records, while second-
ary outcome measure 4 will be based on clinical examin-
ation. Secondary outcome measure 2 will be based on
questionnaires; the first questionnaires will be completed
at the clinical examination related to randomization, the
remaining questionnaires will be sent to the participants’
legal guardians by email and completed online.
Blinding
Owing to the type of the intervention, blinding of pa-
tients, parents and caregivers is not possible. However,
the outcome assessors will be blinded to intervention
and we also consider the number of visits to health
clinics according to medical records (the primary out-
come measure) as blinded. Outcome assessors will be
ENT specialists.
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Blinding of the number of visits at the health-care
centre is ensured by initial blinding of medical records
by an investigator, and hereafter evaluation by two out-
come assessors calculating the number of visits from the
medical records. A third assessor may provide further
evaluation in the event of any disagreement. Blinding of
otoscopical results is ensured by the use of otoscopical
photos, which will be anonymized and evaluated by an
ENT specialist without knowledge of the intervention.
Blinding of quality-of-life measures cannot be obtained
as the child and the parents are not blinded for the
intervention. Therefore, this outcome measure must be
considered at high risk of bias.
Assessment of adverse events
Adverse events and adverse reactions will be assessed at
every ENT visit.
Participant discontinuation and withdrawal
Parents of participating children can withdraw their con-
sent to participate at any time. To be able to analyze data
at an intention-to-treat basis the investigator must ask for
permission to use already collected data for data analysis.
The investigator or treating physician may discontinue
the patient from further participation in the trial if the pa-
tient is diagnosed with any of the exclusion criteria. The
investigator and treating physician will encourage the pa-
tient to continue the follow-up assessment and previously
collected data should be used in further analysis.
We will monitor adherence to the control regimen.
Parents of participating children will be reminded, at the
time point for intervention and assessments, by email.
Those who do not adhere to the control regimen speci-
fied will be further contacted by phone call and email.
Data management
Data will be entered in the data management system Easy
Trial. Easy Trial hold standards according to the Danish
Data Protection Agency, i.e., data are stored on private
servers. Case report forms in electronic format will be
used, as well as case report forms on paper. The paper case
report forms will be entered in the data management sys-
tem twice by two personnel independently to promote data
quality. The personnel will otherwise not be related to the
trial. Patients will be identified by patient identification
number, which is also used at randomization. The trial is
conducted according to regulations by the Danish Data
Protection Agency and only people related to the trial and
the central randomization centre will have access to data.
Missing data will be minimized by checking the com-
pleted questionnaires when returned to the investigators.
If there are any missing answers, the parents of the in-
cluded children will emailed a request to supply the
missing answers.
Statistical plan and data analysis
Based on power (1 − β) = 0.80, α = 0.05 (two-sided) and
standard deviation of five visits to health clinics and
 An estimated eight visits to health clinics during
2 years in the control group and
 An estimated six visits to health clinics during
2 years in the experimental group
we need a sample size of 99 individuals in each inter-
vention group.
As we do not expect that data are normally distrib-
uted, the non-parametric van Elteren test will be used;
thus, we obtain 99/0.86 = 115 participants per interven-
tion group or 230 participants in total [34].
The two interventions will be compared regarding all
outcomes. The analysis of the outcomes will be based on
the intention-to-treat principle, i.e., all randomized par-
ticipants will be included in the analysis, regardless of
how much treatment they have received. Per-protocol
analysis may be considered if important deviations from
the protocol compromise the validity of the intention-
to-treat analysis.
Dichotomous outcomes will be analyzed using logistic
regression, continuous outcomes will be analyzed using
linear regression and count data will be analyzed using
the van Elteren test [34]. Our primary analysis will be
adjusted for the stratification variables used in the
randomization (trial site and type of otitis media). In
secondary analysis, we will adjust all analyses (except
when non-parametric tests are used) for additional sig-
nificant design variables (age, sex, attending daycare,
smokers in the household, diet, family history of otitis
media). The statistical analysis will be described in detail
in a separate paper published before the analysis of the
trial results begins.
If only data are missing on the dependent outcome,
we will use per-protocol data but we will interpret out
results with caution if these missing data potentially bias
our results. Otherwise, if more than 5% of the outcome
data are missing, multiple imputation will be used
(STATA 14). However, the 5% cut-off is not definitive.
The imputation result will be considered the primary
overall result. This analysis will be supplemented by the
following sensitivity analyses:
1. ‘Best-worst-case’ scenario: It will be assumed that all
participants lost to follow-up in the experimental
group have a mean score +2 standard deviations and
have no event; and all those with missing outcomes
in the control group have a mean score of −2 stand-
ard deviations and have an event.
2. ‘Worst-best-case’ scenario: It will be assumed that
all participants lost to follow-up in the experimental
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group have a mean score of −2 standard deviations
and have an event; and all those lost to follow-up in
the control group have a mean score +2 standard
deviations and have no event [35].
Results from both scenarios will be presented in our
trial publication.
If the null hypotheses on the primary outcome measures
are not rejected, our main conclusion will be that we
found no significant difference between the two interven-
tions. The analysis of the remaining outcome measures
will be presented for hypothesis-generating purposes.
Discussion
This trial will provide evidence-based knowledge of the
effects of ventilation tubes in children with middle ear
infections. Furthermore, the effects of ventilation tube
administration in a high-risk population, such as the
Greenlandic, have never, to our knowledge, been investi-
gated and this trial will improve the understanding of
conducting randomized clinical trials in remote areas,
where management of logistical aspects is particularly
challenging.
The strengths of this trial are the inclusion of children
at high risk of developing otitis media and sequelae
thereof; the central randomization regarding both gener-
ation of allocation sequence and allocation concealment;
the primary outcome measure that monitors use of the
health-care system; and our attempts to blind as many
outcome measures as possible. Our trial also has limita-
tions. First, no updated systematic review of the effects
of ventilation tubes is currently available. We refer to
previous Cochrane reviews published in 2008 and 2010,
respectively [18, 23] but the methodology of these re-
views is not optimal and the literature search has not
been sufficiently updated. We are writing a protocol for
a systematic review assessing the effects of ventilation
tubes; this protocol will be registered on PROSPERO. As
soon the protocol is registered, we will perform a litera-
ture search and begin writing the review. Nevertheless, it
is a major methodological limitation that we cannot suf-
ficiently take into account a complete and valid overview
of previous studies on the effects of ventilation tubes.
Further methodological limitations are a lack of blinding
to the intervention regarding a number of the outcome
measures and potential problems with drop-out during
follow-up, owing to lack of interest, migration or
logistics.
Dissemination policy
The Greenlandic population will be informed of the trial
as well as its final results through national media. All
participating health clinics and hospitals will be visited
by the coordinating investigator and instructed in
objectives and screening or inclusion procedures. The
final and interim results will be presented at NUNA
MED, an international conference on Greenlandic medi-
cine and health held every third year.
Trial results will be published in English, Danish and
Greenlandic.
The Government of Greenland will be informed of the
final results before a press release is issued but will have
no influence on the reporting of the results.
Trial status
We launched the randomization on 18 February 2016.
At the end of June, six children had been enrolled and
randomly allocated to a group.
Additional file
Additional file 1: SPIRIT 2013 Checklist. (DOCX 61 kb)
Abbreviation
CONSORT: Consolidated Standards of Reporting Trials; ENT: ear, nose and throat;
SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials
Acknowledgements
The Greenland Institute of Natural Resources is thanked for unconditional
economical support (grant no. 80.11).
Funding
This trial is funded by a grant from Greenland Institute of Natural Resources,
grant no. 80.11. Other funding possibilities will be explored.
Availability of data and materials
The final dataset will be publically available in depersonalized format after
the end of the trial on the Danish Data Archive and Zenodo.
Authors’ contributions
MND participated in the study design, statistical calculations and study
methodology and drafted the manuscript. RGJ contributed to the study design
and methodology and helped to draft the manuscript. JCJ participated in study
design and methodology, carried out statistical calculations and drafted the
manuscript. CG participated in study design and methodology and helped draft
the manuscript. PH designed the study and methodology and contributed to
the manuscript. All authors read and approved the final manuscript. All trial
results whether positive, negative or neutral, will be published, preferably in a
peer-reviewed medical journal. All authorship will be determined according to
International Committee for Medical Journal Editors guidelines for authorship
[36]. The first author is coordinating investigator Malene Nøhr Demant and last
author is responsible investigator Professor Preben Homøe.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The trial will be conducted in compliance with the protocol approved by the
Greenlandic ethics committee (No. 2015-112556) and according to the
International Committee on Harmonization – Good Clinical Practice standards,
as well as the Greenlandic standards of Code of Conduct [37, 38]. No deviation
from the protocol will be implemented without the prior review and approval
of the regulatory authorities, except where it may be necessary to eliminate an
immediate hazard to the trial participants. In such cases, the deviation will be
reported to the regulatory authorities as soon as possible.
Demant et al. Trials  (2017) 18:30 Page 8 of 10
The personnel at the hospitals and health clinics will give written
information about the trial to the child’s legal guardian when the patient is
first considered for screening or inclusion. Further oral and written
information will be given at the first visit by the ENT specialist, where the
written informed consent will be obtained.
It will be stressed that this is a research project, a randomized clinical trial,
and that participation can be withdrawn at any time, without consequences
for future treatment at the health clinic. The cultural aspects of respect of
authorities as well as different ways of expressing decline will be considered.
Furthermore, the trial is registered at ClinicalTrials.gov (NCT02490332) and
approved by the Danish Data Protection Agency (no. 2015-41-4047).
This trial is conducted according to regulations by the Danish Data
Protection Agency. Only people related to the trial and the central
randomization centre will have access to data.
Author details
1Department of Otorhinolaryngology and Maxillofacial Surgery, Zealand
University Hospital, Køge, Denmark. 2Copenhagen Trial Unit, Centre for
Clinical Intervention Research, Rigshospitalet, Copenhagen University
Hospital, Copenhagen, Denmark. 3Department of Cardiology, Holbæk
Hospital, Holbæk, Denmark. 4Institute of Clinical Medicine, Faculty of Health
and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Received: 5 July 2016 Accepted: 21 December 2016
References
1. Rosenfeld RM, Schwartz SR, Pynnonen MA, Tunkel DE, Hussey HM, Fichera
JS, Grimes AM, Hackell JM, Harrison MF, Haskell H, Haynes DS, Kim TW,
Lafreniere DC, LeBlanc K, Mackey WL, et al. Clinical practice guideline:
tympanostomy tubes in children. Otolaryngol Head Neck Surg. 2013;
149(1 Suppl):S1–35.
2. Sidell D, Shapiro NL, Bhattacharyya N. Demographic influences on antibiotic
prescribing for pediatric acute otitis media. Otolaryngol Head Neck Surg.
2012;146(4):653–8.
3. Rosenfeld RM, Shin JJ, Schwartz SR, Coggins R, Gagnon L, Hackell JM,
Hoelting D, Hunter LL, Kummer AW, Payne SC, Poe DS, Veling M, Vila PM,
Walsh SA, Corrigan MD. Clinical practice guideline: otitis media with
effusion executive summary (update). Otolaryngol Head Neck Surg. 2016;
154(2):201–14.
4. Ahmed S, Shapiro NL, Bhattacharyya N. Incremental health care utilization and
costs for acute otitis media in children. Laryngoscope. 2014;124(1):301–5.
5. Homøe P, Jensen RG. Mellemørebetændelse i Grønland (Middle ear
infections in Greenland). Månedsskrift for Almen Praksis (Journal of The
Danish College of General Practitioners). 2013;91:228–37.
6. Homøe P, Christensen RB, Bretlau P. Prevalence of otitis media in a survey
of 591 unselected Greenlandic children. Int J Pediatr Otorhinolaryngol.
1996;36(3):215–30.
7. Koch A, Homøe P, Pipper C, Hjuler T, Melbye M. Chronic suppurative otitis
media in a birth cohort of children in Greenland: population-based study of
incidence and risk factors. Pediatr Infect Dis J. 2011;30(1):25–9.
8. Jensen RG, Homøe P, Andersson M, Koch A. Long-term follow-up of chronic
suppurative otitis media in a high-risk children cohort. Int J Pediatr
Otorhinolaryngol. 2011;75(7):948–54.
9. Jensen RG, Koch A, Homøe P. The risk of hearing loss in a population with a
high prevalence of chronic suppurative otitis media. Int J Pediatr
Otorhinolaryngol. 2013;77(9):1530–5.
10. Homøe P, Christensen RB, Bretlau P. Acute otitis media and sociomedical
risk factors among unselected children in Greenland. Int J Pediatr
Otorhinolaryngol. 1999;49(1):37–52.
11. Morris PS, Leach AJ, Silberberg P, Mellon G, Wilson C, Hamilton E, Beissbarth
J. Otitis media in young Aboriginal children from remote communities in
Northern and Central Australia: a cross-sectional survey. BMC Pediatr.
2005;5:27.
12. WHO. Report of a WHO/CIBA foundation workshop 1996, prevention of
hearing impairment from chronic otitis media, London, UK, 19–21
November 1996. Geneva: WHO; 1996.
13. Homøe P, Prag J, Farholt S, Henrichsen J, Hornsleth A, Kilian M, Jensen JS.
High rate of nasopharyngeal carriage of potential pathogens among
children in Greenland: results of a clinical survey of middle-ear disease.
Clin Infect Dis. 1996;23(5):1081–90.
14. Jacoby P, Carville KS, Hall G, Riley TV, Bowman J, Leach AJ, Lehmann D.
Crowding and other strong predictors of upper respiratory tract carriage of
otitis media-related bacteria in Australian Aboriginal and non-Aboriginal
children. Pediatr Infect Dis J. 2011;30(6):480–5.
15. Smith-Vaughan H, Byun R, Nadkarni M, Jacques NA, Hunter N, Halpin S,
Morris PS, Leach AJ. Measuring nasal bacterial load and its association with
otitis media. BMC Ear Nose Throat Disord. 2006;6:10.
16. Hoffman HJ, Daly KA, Bainbridge KE, Casselbrant ML, Homøe P, Kvestad E,
Kvaerner KJ, Vernacchio L. Panel 1: Epidemiology, natural history, and risk
factors. Otolaryngol Head Neck Surg. 2013;148(4 Suppl):E1–E25.
17. Tos M. Upon the relationship between secretory otitis in childhood and
chronic otitis and its sequelae in adults. J Laryngol Otol. 2007;95(10):1011–22.
18. McDonald S, Langton Hewer CD, Nunez DA. Grommets (ventilation tubes)
for recurrent acute otitis media in children. Cochrane Database Syst Rev.
2008;4:CD004741.
19. Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson
MA, Joffe MD, Miller DT, Rosenfeld RM, Sevilla XD, Schwartz RH, Thomas PA,
Tunkel DE. The diagnosis and management of acute otitis media. Pediatrics.
2013;131(3):e964–99.
20. National Institute for Health and Care Excellence. www.nice.org.uk/
guidance/CG60 [Accessed 2 January 2016]
21. Heidemann CH, Lous J, Berg J, Christensen JJ, Håkonsen SJ, Jakobsen M,
Johansen CJ, Nielsen LH, Hansen MP, Poulsen A, Schousboe LP, Skrubeltang
C, Vind AB, Homøe P. Danish guidelines on management of otitis media in
preschool children. Int J Pediatr Otorhinolaryngol. 2016;87:154–63.
22. Schilder AGM, Lok W, Rovers MM. International perspectives on
management of acute otitis media: a qualitative review. Int J Pediatr
Otorhinolaryngol. 2004;68(1):29–36.
23. Browning GG, Rovers MM, Williamson I, Lous J, Burton MJ. Grommets
(ventilation tubes) for hearing loss associated with otitis media with effusion
in children. Cochrane Database Syst Rev. 2010;10:CD001801.
24. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P,
Schünemann HJ. GRADE: an emerging consensus on rating quality of
evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
25. Moher D, Schulz K, Altman D. The CONSORT statement: revised
recommendations for improving the quality of reports of parallel group
randomized trials. BMC Med Res Methodol. 2001;1:2.
26. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K,
et al. SPIRIT 2013 statement: defining standard protocol items for clinical
trials. Ann Intern Med. 2013;158:200–7.
27. Niclasen B, Mulvad G. Health care and health care delivery in Greenland.
Int J Circumpolar Health. 2010;69(5):437.
28. Koch A, Sørensen P, Homøe P, Mølbak K, Pedersen FK, Mortensen T,
Elberling H, Eriksen AM, Olsen OR, Melbye M. Population-based study of
acute respiratory infections in children, Greenland. Emerg Infect Dis.
2002;8(6):586–93.
29. Rosenfeld RM, Goldsmith AJ, Tetlus L. Quality of life for children with otitis
media. Arch Otolaryngol Head Neck Surg. 1997;123(10):1049–54.
30. Heidemann CH, Godballe C, Kjeldsen AD, Johansen EC, Faber CE, Lauridsen
HH. The Otitis Media-6 questionnaire: psychometric properties with
emphasis on factor structure and interpretability. Health Qual Life
Outcomes. 2013;11:201.
31. Boruk M, Lee P, Faynzilbert Y, Rosenfeld RM. Caregiver well-being and child
quality of life. Otolaryngol Head Neck Surg. 2007;136:159–68.
32. Heidemann CH, Godballe C, Kjeldsen AD, Johansen EC, Faber CE, Lauridsen
HH. Otitis media and caregiver quality of life: psychometric properties of the
modified Danish Version of the Caregiver Impact Questionnaire. Otolaryngol
Head Neck Surg. 2014;151(1):142–9.
33. European Parliament and the Council of the European Union. Directive
2001/20/EC of the European Parliament and of the Council of 4 April 2001
on the approximation of the laws, regulations and administrative provisions
of the Member States relating to the implementation of good clinical
practice in the conduct of clinical trials on medicinal products for human
use. 2001. https://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_20/dir_
2001_20_en.pdf
34. Jakobsen JC, Tamborrino M, Winkel P, Haase N, Perner A, Wetterslev J, et al.
Count data analysis in randomised clinical trials. J Biometrics Biostatistics.
2015;6:227.
35. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for
statistical and clinical significance in systematic reviews with meta-analytic
methods. BMC Med Res Methodol. 2014;14:120.
Demant et al. Trials  (2017) 18:30 Page 9 of 10
36. International Committee of Medical Journal Editors, Recommendations,
Defining the Role of Authors and Contributors, http://www.icmje.org/
recommendations/browse/roles-and-responsibilities/defining-the-role-of-
authors-and-contributors.html [Accessed 01 Jan 2016].
37. ICH harmonised tripartite guideline: guideline for good clinical practice.
Essential documents for the conduct of a clinical trial. J Postgraduate Med.
2001;47(4):264–7.
38. Greenlandic Medical Society, Code of conduct. http://gmsnet.dk/test/wp-
content/uploads/2015/10/CodeOfConduct_final.pdf [Accessed 2 Jan 2016]
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Demant et al. Trials  (2017) 18:30 Page 10 of 10
